09:21 AM EST, 12/16/2024 (MT Newswires) -- Sinovac Biotech ( SVA ) said Monday that it has begun enrollment in a late-stage study of its investigational bivalent vaccine targeting Hand, Foot, and Mouth Disease, or HFMD, caused by enterovirus 71 and coxsackievirus 16.

The company said the trial will evaluate the potential vaccine's efficacy, safety, and immune response in children aged 6 to 71 months.

Sinovac said it is also developing a tetravalent vaccine targeting four major enteroviruses, which was recently approved for clinical trials.